Table 4 Comparison between our study and the other LD-SCLC studies

Turissi et al. [24]

all

CDDP plus ETP

45Gy, once/ twice a daily, concurrent

MST:19 months (once)

MST:23 months (twice)

Jeremic et al.

≥70

CBDCA plus ETP

45Gy, twice a daily, concurrent

2-year survival:32%

5-year survival:13%

Okamoto et al. [25]

≥70

CDDP plus ETP

45Gy, twice a daily, concurrent

MST:24.1 months

This study

≥70

CBDCA plus IRINOTECAN

54Gy, once a daily, sequential

MST:27.1 months